41 results
10-K
2023 FY
EX-31.2
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
, to the registrant’s auditors and the audit committee of the registrant’s board of directors
All significant deficiencies and material weaknesses in the design
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
qualified members of the Board, particularly to serve on the Audit Committee and Compensation Committee, and qualified executive officers.
We … our independent registered public accounting firm audit our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act
10-K
2023 FY
EX-31.1
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
auditors and the audit committee of the registrant’s board of directors:
All significant deficiencies and material weaknesses in the design
8-K
akrjsjwlmk 3m
13 Mar 24
Departure of Directors or Certain Officers
4:30pm
8-K
2xzvya342 iv226w
1 Dec 23
Departure of Directors or Certain Officers
5:00pm
8-K
EX-10.1
qllz9e64vhmy9760gm1v
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
8-K
qkxet trzpyu
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
8-K
qsyr6acg 57v9j5g
25 Oct 23
Departure of Directors or Certain Officers
4:45pm
10-Q
EX-31.2
q1ilol7juo3ab11fom
15 Sep 23
Quarterly report
4:45pm
10-Q
EX-31.1
jp3qg3
15 Sep 23
Quarterly report
4:45pm
8-K
EX-1.1
gw7g berxr5aqvm32
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
424B4
0qeue4l69q
4 Aug 23
Prospectus supplement with pricing info
1:01pm
424B1
8ae 92x0s8f
4 Aug 23
Prospectus with pricing info
12:59pm